Suchergebnisse - "MCRPC"

PubPharm (905)

11

Assessment of PSMA Expression of Healthy Organs in Different Stages of Prostate Cancer Using [68Ga]Ga-PSMA-11-PET Examinations

enthalten in: Cancers | 2024

von Einspieler, H. | Kluge, K. | Haberl, D. | +11

12

Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models

enthalten in: The Prostate | 2024

von Jasmine, S. | Mandl, A. | Krueger, T. | +18

13

Second-line treatment options in metastatic castration-resistant prostate cancer after progression on first-line androgen-receptor targeting therapies : A systematic review and Bayesian network analysis

enthalten in: Critical reviews in oncology/hematology | 2024

von Xiong, X. | Zhang, S. | Zheng, W. | +6

14

Metastatic castration resistant prostate cancer patients' experience with Radium-223 treatment in Japan

enthalten in: Future oncology (London, England) | 2024

von Akakura, K. | Uemura, H. | Kawakami, S. | +5

15

Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis : A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate Cancer

enthalten in: Clinical genitourinary cancer | 2024

von Tashiro, K. | Kimura, S. | Tsuzuki, S. | +15

16

177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer : a real-world study

enthalten in: European journal of nuclear medicine and molecular imaging | 2024

von Satapathy, S. | Yadav, M. | Ballal, S. | +2

17

177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer : A Review of the Evidence and Implications for Canadian Clinical Practice

enthalten in: Current oncology (Toronto, Ont.) | 2024

von Chi, K. | Yip, S. | Bauman, G. | +10

18

First clinical and oncological experiences with triplet therapy for high-volume metastatic hormone-sensitive prostate cancer

enthalten in: Urologie (Heidelberg, Germany) | 2024

von Wenzel, M. | Hoeh, B. | Kasparek, J. | +5

19

Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [177Lu]Ludotadipep in Patients With Metastatic Castration-Resistant Prostate Cancer

enthalten in: Korean journal of radiology | 2024

von Ha, S. | O, J. | Park, C. | +5

20

PARP inhibitors for prostate cancer

enthalten in: Seminars in oncology | 2024

von Longoria, O. | Beije, N. | de Bono, J.